News

Block Listing Interim Review
Block Listing Interim Review
October 8, 2018

Block Admission Return

Director/PDMR Shareholding
Director/PDMR Shareholding
October 4, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") on 2 October 2018 that it purchased 20,000 Ordinary Shares of 1p in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”).  Following the purchase, Vulpes has a total direct and indirect interest in 60,337,088 equivalent to 20.44% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
October 1, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") on 1 October 2018 that on 27 and 28 September 2018, it purchased 81 and 910,608 Ordinary Shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”).  Following the purchase, Vulpes has a total direct and indirect interest in 60,317,088 equivalent to 20.43% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
September 21, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 21 September 2018, it purchased 75,520 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 59,406,399 equivalent to 20.13% of Proteome Sciences' total issued share capital.

Director/PDMR shareholding
Director/PDMR shareholding
September 12, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 11 September 2018, it purchased 601,582 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 59,330,879 equivalent to 20.01% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
September 7, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 13 August 2018, it purchased 469,866 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.60p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 58,729,297 equivalent to 19.89% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
August 14, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 13 August 2018, it purchased 500,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.50p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 58,259,431 equivalent to 19.74% of Proteome Sciences' total issued share capital.

Director PDMR Shareholding
Director PDMR Shareholding
August 9, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 7 August 2018, it purchased 1,400,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.50p per Ordinary Share (the "Purchase"). Following the purchase, Vulpes has a total direct and indirect interest in 57,759,431 equivalent to 19.6% of Proteome Sciences' total issued share capital

Director/PDMR Shareholding
Director/PDMR Shareholding
August 2, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 1 August 2018, it purchased 328,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.50p per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 56,359,431 equivalent to 19.09% of Proteome Sciences' total issued share capital.

Director/PDMR Shareholding
Director/PDMR Shareholding
August 1, 2018

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 27 July 2018, it purchased 525,000 ordinary shares and 118,000 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at 3.49p and 3.5p respectively per Ordinary Share (the “Purchase”). Following the purchase, Vulpes has a total direct and indirect interest in 56,031,431 equivalent to 18.98% of Proteome Sciences' total issued share capital.